He Chaobin, Huang Xin, Zhang Yu, Cai Zhiyuan, Lin Xiaojun, Li Shengping
State Key Laboratory of Oncology in South China, Department of Pancreatobiliary Surgery, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.
Front Oncol. 2020 Jan 22;10:6. doi: 10.3389/fonc.2020.00006. eCollection 2020.
Locally advanced pancreatic cancer (LAPC) has a dismal prognosis even after standard chemotherapy, and local progression contributes to nearly one-third of the deaths of these patients. As a local destructive method, irreversible electroporation (IRE) can feasibly treat LAPC. The aim of this study was to evaluate IRE combined with chemotherapy as a new treatment and compare its efficacy with that of chemotherapy alone in patients with LAPC. The data of LAPC patients who received chemotherapy with or without IRE were extracted from Surveillance, Epidemiology, and End Results (SEER) database and medical records of Sun Yat-sen University Cancer Center (SYSUCC). The efficacy of these two treatments was compared using propensity score matching (PSM) analysis. LAPC patients treated with the combination therapy had better overall survival (OS). Significantly higher cancer-specific survival (CSS) and progression-free survival (PFS) rates were also observed in patients after IRE combined with chemotherapy, compared with chemotherapy alone. IRE combined with chemotherapy was established as a favorable factor for OS, CSS, and PFS in LAPC patients. This combination method may be a more suitable treatment for patients with LAPC.
局部晚期胰腺癌（LAPC）即使经过标准化化疗，预后依然很差，局部进展导致近三分之一的此类患者死亡。作为一种局部破坏方法，不可逆电穿孔（IRE）能够切实治疗LAPC。本研究的目的是评估IRE联合化疗作为一种新的治疗方法，并将其疗效与单纯化疗在LAPC患者中的疗效进行比较。接受或未接受IRE化疗的LAPC患者的数据从监测、流行病学和最终结果（SEER）数据库以及中山大学肿瘤防治中心（SYSUCC）的医疗记录中提取。使用倾向评分匹配（PSM）分析比较这两种治疗方法的疗效。接受联合治疗的LAPC患者总生存期（OS）更好。与单纯化疗相比，IRE联合化疗后的患者癌症特异性生存期（CSS）和无进展生存期（PFS）率也显著更高。IRE联合化疗被确定为LAPC患者OS、CSS和PFS的有利因素。这种联合方法可能是LAPC患者更合适的治疗方法。
